CSF1R is altered in 1.53% of malignant solid tumor patients with CSF1R Mutation present in 1.36% of all malignant solid tumor patients [4].

CSF1R Mutation is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain CSF1R Mutation and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

CSF1R is altered in 3.75% of melanoma patients with CSF1R Mutation present in 3.59% of all melanoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 2.21% of malignant uterine neoplasm patients with CSF1R Mutation present in 1.9% of all malignant uterine neoplasm patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.71% of esophageal squamous cell carcinoma patients with CSF1R Mutation present in 1.85% of all esophageal squamous cell carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.74% of non-small cell lung carcinoma patients with CSF1R Mutation present in 1.69% of all non-small cell lung carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.66% of bladder carcinoma patients with CSF1R Mutation present in 1.68% of all bladder carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.78% of lung carcinoma patients with CSF1R Mutation present in 1.68% of all lung carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.83% of colorectal carcinoma patients with CSF1R Mutation present in 1.53% of all colorectal carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.3% of gastric adenocarcinoma patients with CSF1R Mutation present in 1.35% of all gastric adenocarcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.18% of head and neck carcinoma patients with CSF1R Mutation present in 1.13% of all head and neck carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.66% of adenocarcinoma of the gastroesophageal junction patients with CSF1R Mutation present in 1.02% of all adenocarcinoma of the gastroesophageal junction patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.17% of ovarian carcinoma patients with CSF1R Mutation present in 0.94% of all ovarian carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 0.92% of pancreatic carcinoma patients with CSF1R Mutation present in 0.85% of all pancreatic carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.04% of bile duct carcinoma patients with CSF1R Mutation present in 0.83% of all bile duct carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 1.22% of gallbladder carcinoma patients with CSF1R Mutation present in 0.83% of all gallbladder carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 0.68% of breast carcinoma patients with CSF1R Mutation present in 0.53% of all breast carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 0.72% of cervical carcinoma patients with CSF1R Mutation present in 0.49% of all cervical carcinoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 0.51% of soft tissue sarcoma patients with CSF1R Mutation present in 0.42% of all soft tissue sarcoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R is altered in 0.28% of B-cell non-hodgkin lymphoma patients with CSF1R Mutation present in 0.29% of all B-cell non-hodgkin lymphoma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CSF1R is altered in 0.61% of multiple myeloma patients [4].

CSF1R Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].